再発性または難治性のCD20陽性非ホジキンリンパ腫の成人患者におけるリツキシマブと併用したTAK-981の投与に関する研究

基本情報

NCT ID

NCT04074330

ステータス

中止

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

38

治験依頼者名

Takeda

概要

This study is about a medicine called TAK-981 given with rituximab, used to treat adults with relapsed or refractory CD20-positive non-Hodgkin lymphoma. This study has 2 parts. The main aims of the study are: * To check for side effects from treatment with TAK-981 given with rituximab. * To check how much TAK-981 participants can tolerate. * To check if participants with diffuse large B-cell lymphoma or follicular lymphoma respond well to treatment. Participants will receive TAK-981 and rituximab in 21-day cycles. They will continue treatment for about 12 months unless their condition gets worse (disease progression), they cannot tolerate the treatment, or they leave the study for certain reasons.

対象疾患

介入

依頼者（Sponsor）

実施施設 (5)